Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up (Q46985103)

27 December 2017

title

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up (English)

1 reference

27 December 2017

proliferative diabetic retinopathy

1 reference

1 reference

1 reference

4

1 reference

27 December 2017

author name string

J F Arevalo

1

1 reference

27 December 2017

L Wu

2

1 reference

27 December 2017

J G Sanchez

3

1 reference

27 December 2017

M J Saravia

5

1 reference

27 December 2017

C F Fernandez

6

1 reference

27 December 2017

T Evans

7

1 reference

27 December 2017

publication date

21 September 2007

1 reference

27 December 2017

published in

Eye

1 reference

27 December 2017

volume

23

1 reference

27 December 2017

page(s)

117-123

1 reference

27 December 2017

issue

1

1 reference

27 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.eye.6702980

exact match

0 references

cites work

Global and societal implications of the diabetes epidemic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Extensive argon laser photocoagulation in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

7 January 2021

Single versus Multiple Treatment Sessions of Argon Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

7 January 2021

Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

7 January 2021

Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

7 January 2021

Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

7 January 2021

Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

7 January 2021

Randomized comparison of krypton versus argon scatter photocoagulation for diabetic disc neovascularization. The Krypton Argon Regression Neovascularization Study report number 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.EYE.6702980

1 reference

7 January 2021

Identifiers

DOI

10.1038/SJ.EYE.6702980

1 reference

27 December 2017

PubMed ID

17891058

1 reference

27 December 2017